BRAF mutation is associated with early stage disease and improved outcome in patients with low-grade serous ovarian cancer.
作者： Rachel N. Grisham , Gopa Iyer , Karuna Garg , Deborah DeLair , David M. Hyman
DOI: 10.1002/CNCR.27782
关键词: V600E 、 Serous fluid 、 Ovarian cancer 、 Internal medicine 、 Oncology 、 Survival analysis 、 Cancer 、 Chemotherapy 、 Stage (cooking) 、 Cancer research 、 KRAS 、 Medicine
摘要: … remained alive at a median follow-up of 43.3 months (range, 1.9–129.3 months), with the suggestion of improved overall survival compared with patients who had KRAS mutant or …
sci-hub.se 参考文章(28)
Diane C. Bodurka, Michael T. Deavers, Chunqiao Tian, Charlotte C. Sun, Anais Malpica, Robert L. Coleman, Karen H. Lu, Anil K. Sood, Michael J. Birrer, Robert Ozols, Rebecca Baergen, Robert E. Emerson, Margaret Steinhoff, Behnaz Behmaram, Golnar Rasty, David M. Gershenson, Reclassification of serous ovarian carcinoma by a 2-tier system: A Gynecologic Oncology Group study Cancer. ,vol. 118, pp. 3087- 3094 ,(2012) , 10.1002/CNCR.26618
Ie-Ming Shih, Robert J. Kurman, Ovarian Tumorigenesis : A Proposed Model Based on Morphological and Molecular Genetic Analysis American Journal of Pathology. ,vol. 164, pp. 1511- 1518 ,(2004) , 10.1016/S0002-9440(10)63708-X
S. E. Hilary Russell, W. Glenn McCluggage, A multistep model for ovarian tumorigenesis: the value of mutation analysis in the KRAS and BRAF genes. The Journal of Pathology. ,vol. 203, pp. 617- 619 ,(2004) , 10.1002/PATH.1563
Doris Mayr, Astrid Hirschmann, Udo Löhrs, Joachim Diebold, KRAS and BRAF mutations in ovarian tumors: A comprehensive study of invasive carcinomas, borderline tumors and extraovarian implants Gynecologic Oncology. ,vol. 103, pp. 883- 887 ,(2006) , 10.1016/J.YGYNO.2006.05.029
E. W. Joseph, C. A. Pratilas, P. I. Poulikakos, M. Tadi, W. Wang, B. S. Taylor, E. Halilovic, Y. Persaud, F. Xing, A. Viale, J. Tsai, P. B. Chapman, G. Bollag, D. B. Solit, N. Rosen, The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner Proceedings of the National Academy of Sciences of the United States of America. ,vol. 107, pp. 14903- 14908 ,(2010) , 10.1073/PNAS.1008990107
Chung-Liang Ho, Robert J. Kurman, Reiko Dehari, Tian-Li Wang, Ie-Ming Shih, Mutations of BRAF and KRAS Precede the Development of Ovarian Serous Borderline Tumors Cancer Research. ,vol. 64, pp. 6915- 6918 ,(2004) , 10.1158/0008-5472.CAN-04-2067
Agnes Colanta, Oscar Lin, Laura Tafe, Ronald Ghossein, Khedoudja Nafa, Talia Mitchell, Marc Ladanyi, Maria Arcila, BRAF mutation analysis of fine-needle aspiration biopsies of papillary thyroid carcinoma: impact on diagnosis and prognosis. Acta Cytologica. ,vol. 55, pp. 563- 569 ,(2011) , 10.1159/000333272
Ann E. Smith Sehdev, Paul S. Sehdev, Robert J. Kurman, Noninvasive and invasive micropapillary (low-grade) serous carcinoma of the ovary: a clinicopathologic analysis of 135 cases. The American Journal of Surgical Pathology. ,vol. 27, pp. 725- 736 ,(2003) , 10.1097/00000478-200306000-00003
Hyun S. Shvartsman, Charlotte C. Sun, Diane C. Bodurka, Vrinda Mahajan, Marta Crispens, Karen H. Lu, Michael T. Deavers, Anais Malpica, Elvio G. Silva, David M. Gershenson, Comparison of the clinical behavior of newly diagnosed stages II-IV low-grade serous carcinoma of the ovary with that of serous ovarian tumors of low malignant potential that recur as low-grade serous carcinoma Gynecologic Oncology. ,vol. 105, pp. 625- 629 ,(2007) , 10.1016/J.YGYNO.2007.01.030
Gad Singer, Robert St??hr, Leslie Cope, Reiko Dehari, Arndt Hartmann, Deng-Fan Cao, Tian-Li Wang, Robert J Kurman, Ie-Ming Shih, Patterns of p53 mutations separate ovarian serous borderline tumors and low- and high-grade carcinomas and provide support for a new model of ovarian carcinogenesis: A mutational analysis with immunohistochemical correlation The American Journal of Surgical Pathology. ,vol. 29, pp. 218- 224 ,(2005) , 10.1097/01.PAS.0000146025.91953.8D